196 related articles for article (PubMed ID: 28251274)
1. Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.
Theelen J; Braun J; Hörzer H; Kloke BP; Ott M; Pizzitola I; Schirmer U; Miller M
Cancer Immunol Immunother; 2017 May; 66(5):673-681. PubMed ID: 28251274
[No Abstract] [Full Text] [Related]
2. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
[No Abstract] [Full Text] [Related]
3. CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.
Diken M; Attig S; Grunwitz C; Kranz L; Simon P; van de Roemer N; Vascotto F; Kreiter S
Hum Vaccin Immunother; 2013 Sep; 9(9):2025-32. PubMed ID: 23877042
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
Kloke BP; Mahr A; Jabulowsky RA; Kutscher S; Rae R; Britten CM
Cancer Immunol Immunother; 2015 Jul; 64(7):923-30. PubMed ID: 25548093
[No Abstract] [Full Text] [Related]
5. CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Kranz LM; Birtel M; Hilscher L; Grunwitz C; Petschenka J; Vascotto F; Vormehr M; Voss RH; Kreiter S; Diken M
Hum Vaccin Immunother; 2016 Nov; 12(11):2805-2812. PubMed ID: 27435168
[No Abstract] [Full Text] [Related]
6. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
7. Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.
Kloke BP; Kutscher S; Rae R; Kvistborg P; Britten CM; Hadrup SR
Cancer Immunol Immunother; 2013 May; 62(5):975-81. PubMed ID: 23299564
[No Abstract] [Full Text] [Related]
8. Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.
Kloke BP; Rae R; Mahr A; Burkhardt UE; Kvistborg P; Britten CM
Cancer Immunol Immunother; 2014 Jul; 63(7):749-55. PubMed ID: 24190545
[No Abstract] [Full Text] [Related]
9. Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany.
Hobohm K; Seppmann T; Britten CM; Hoff H
Cancer Immunol Immunother; 2012 Jan; 61(1):137-43. PubMed ID: 22048716
[No Abstract] [Full Text] [Related]
10. CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16
Beck J; Birtel M; Reidenbach D; Salomon N; Diken M
Hum Vaccin Immunother; 2018; 14(12):2864-2873. PubMed ID: 30111232
[TBL] [Abstract][Full Text] [Related]
11. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany.
Diken M; Widenmeyer M; Gouttefangeas C; Welters MJ; Britten CM
Cancer Immunol Immunother; 2010 Sep; 59(9):1417-23. PubMed ID: 19771427
[No Abstract] [Full Text] [Related]
12. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015.
Miller M; Jahndel V; Kutscher S; Mahr A; Rae R; Kloke BP
Cancer Immunol Immunother; 2016 Oct; 65(10):1277-87. PubMed ID: 27259506
[No Abstract] [Full Text] [Related]
13. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany.
Welters MJ; van Montfoort N; Khan S; Meyer RG; Britten CM
Cancer Immunol Immunother; 2009 May; 58(5):777-87. PubMed ID: 18982325
[No Abstract] [Full Text] [Related]
14. CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.
Singh SK; Laske K; Gouttefangeas C; Britten CM; Welters MJ
Cancer Immunol Immunother; 2011 Mar; 60(3):443-50. PubMed ID: 21104411
[No Abstract] [Full Text] [Related]
15. The Summit for Cancer Immunotherapy (Summit4CI), June 26-29, 2016 Halifax, Canada.
Wouters MCA; Laumont CM; Chen B; Han SJ; Matuszewska K; Potts K; Boudreau JE; Krawczyk CM
Cancer Immunol Immunother; 2017 Jun; 66(6):811-818. PubMed ID: 28409191
[No Abstract] [Full Text] [Related]
16. CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Kranz LM; Birtel M; Krienke C; Grunwitz C; Petschenka J; Reuter KC; van de Roemer N; Vascotto F; Vormehr M; Kreiter S; Diken M
Hum Vaccin Immunother; 2016; 12(1):213-21. PubMed ID: 26186022
[No Abstract] [Full Text] [Related]
17. CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.
Beck JD; Birtel M; Haefner E; Keil IS; Reidenbach D; Salomon N; Yildiz IG; Diken M
Hum Vaccin Immunother; 2020 Apr; 16(4):808-815. PubMed ID: 31584850
[No Abstract] [Full Text] [Related]
18. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
Locy H; de Mey S; de Mey W; De Ridder M; Thielemans K; Maenhout SK
Front Immunol; 2018; 9():2909. PubMed ID: 30619273
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
20. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
